KEI Comments on NIH Exclusive Licenses for CAR T Technologies to Kite/Gilead

On Monday July 29, 2019, Knowledge Ecology International (KEI) submitted joint comments to the NIH on behalf of KEI, Social Security Works (SSW), Universities Allied for Essential Medicines (UAEM), Union for Affordable Cancer Treatment (UACT), and Clare Love, a cancer… Continue Reading

KEI Letter to US House Oversight Committee on NIH Misconduct and Lack of Transparency

On July 22, 2019, Knowledge Ecology International submitted a letter to the US House of Representative’s Committee on Oversight and Reform regarding the National Institutes of Health’s (NIH) lack of transparency in its exclusive licensing processes. Prior to executing an… Continue Reading

KEI letter to FTC regarding interoperability remedies to address unlawful and anti-competitive actions by Facebook

KEI letter to FTC regarding interoperability remedies to address unlawful and anti-competitive actions by Facebook Today KEI sent a letter to the U.S. Federal Trade Commission (FTC), asking that the FTC require Facebook to extend interoperability remedies to third party… Continue Reading

KEI and UACT comment on NIH license to Molecular Targeting Technologies, Inc. over Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors

On July 2, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 28063 on the “Prospective Grant of Exclusive Patent License: Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors” from the National Institutes of Health (NIH). The proposed… Continue Reading